Literature DB >> 22246505

Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.

Carole Saison1, Virginie Helias, Bryan A Ballif, Thierry Peyrard, Hervé Puy, Toru Miyazaki, Sébastien Perrot, Muriel Vayssier-Taussat, Mauro Waldner, Pierre-Yves Le Pennec, Jean-Pierre Cartron, Lionel Arnaud.   

Abstract

The breast cancer resistance protein, also known as ABCG2, is one of the most highly studied ATP-binding cassette (ABC) transporters because of its ability to confer multidrug resistance. The lack of information on the physiological role of ABCG2 in humans severely limits cancer chemotherapeutic approaches targeting this transporter. We report here that ABCG2 comprises the molecular basis of a new blood group system (Junior, Jr) and that individuals of the Jr(a-) blood type have inherited two null alleles of ABCG2. We identified five frameshift and three nonsense mutations in ABCG2. We also show that the prevalence of the Jr(a-) blood type in the Japanese and European Gypsy populations is related to the p.Gln126* and p.Arg236* protein alterations, respectively. The identification of ABCG2(-/-) (Jr(a-)) individuals who appear phenotypically normal is an essential step toward targeting ABCG2 in cancer and also in understanding the physiological and pharmacological roles of this promiscuous transporter in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246505      PMCID: PMC3653631          DOI: 10.1038/ng.1070

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  31 in total

1.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

2.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

Authors:  Yasuo Imai; Minoru Nakane; Kumie Kage; Satomi Tsukahara; Etsuko Ishikawa; Takashi Tsuruo; Yoshio Miki; Yoshikazu Sugimoto
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

3.  Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.

Authors:  Hirotaka Matsuo; Tappei Takada; Kimiyoshi Ichida; Takahiro Nakamura; Akiyoshi Nakayama; Yuki Ikebuchi; Kousei Ito; Yasuyoshi Kusanagi; Toshinori Chiba; Shin Tadokoro; Yuzo Takada; Yuji Oikawa; Hiroki Inoue; Koji Suzuki; Rieko Okada; Junichiro Nishiyama; Hideharu Domoto; Satoru Watanabe; Masanori Fujita; Yuji Morimoto; Mariko Naito; Kazuko Nishio; Asahi Hishida; Kenji Wakai; Yatami Asai; Kazuki Niwa; Keiko Kamakura; Shigeaki Nonoyama; Yutaka Sakurai; Tatsuo Hosoya; Yoshikatsu Kanai; Hiroshi Suzuki; Nobuyuki Hamajima; Nariyoshi Shinomiya
Journal:  Sci Transl Med       Date:  2009-11-04       Impact factor: 17.956

4.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.

Authors:  Christian W Scharenberg; Michael A Harkey; Beverly Torok-Storb
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

5.  Identification and functional assessment of BCRP polymorphisms in a Korean population.

Authors:  Sang Seop Lee; Hye-Eun Jeong; Joo-Mi Yi; Hyun-Ju Jung; Jae-Eun Jang; Eun-Young Kim; Su-Jun Lee; Jae-Gook Shin
Journal:  Drug Metab Dispos       Date:  2007-01-19       Impact factor: 3.922

6.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

7.  Fatal hemolytic disease of the fetus and newborn associated with anti-Jr.

Authors:  Thierry Peyrard; Bach-Nga Pham; Lionel Arnaud; Sophie Fleutiaux; Yves Brossard; Bénédicte Guerin; Isabelle Desmoulins; Philippe Rouger; Pierre-Yves Le Pennec
Journal:  Transfusion       Date:  2008-06-02       Impact factor: 3.157

Review 8.  Clinical significance of anti-Jra: report of two cases and review of the literature.

Authors:  MeeAe Y Kwon; Leon Su; Patricia A Arndt; George Garratty; Douglas P Blackall
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

9.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.

Authors:  Owen M Woodward; Anna Köttgen; Josef Coresh; Eric Boerwinkle; William B Guggino; Michael Köttgen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

Review 10.  Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

Authors:  Kohji Noguchi; Kazuhiro Katayama; Junko Mitsuhashi; Yoshikazu Sugimoto
Journal:  Adv Drug Deliv Rev       Date:  2008-12-03       Impact factor: 15.470

View more
  39 in total

Review 1.  Zebrafish as a model system to delineate the role of heme and iron metabolism during erythropoiesis.

Authors:  Jianbing Zhang; Iqbal Hamza
Journal:  Mol Genet Metab       Date:  2018-12-24       Impact factor: 4.797

2.  Mitochondrial heme: an exit strategy at last.

Authors:  Mark D Fleming; Iqbal Hamza
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

3.  Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.

Authors:  Geoff Daniels; Bryan A Ballif; Virginie Helias; Carole Saison; Shane Grimsley; Lucienne Mannessier; Hein Hustinx; Edmond Lee; Jean-Pierre Cartron; Thierry Peyrard; Lionel Arnaud
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

4.  Genomic coordinates and continental distribution of 120 blood group variants reported by the 1000 Genomes Project.

Authors:  Celina Montemayor-Garcia; Panagiota Karagianni; David A Stiles; Erika M Reese; Danielle A Smellie; Debrean A Loy; Kimberly Y Levy; Magdalene Nwokocha; Marina U Bueno; Jeffery L Miller; Harvey G Klein
Journal:  Transfusion       Date:  2018-10-12       Impact factor: 3.157

5.  "OMICs" reveal the molecular basis of a rare blood group.

Authors:  John D Schuetz
Journal:  Blood       Date:  2020-02-06       Impact factor: 22.113

Review 6.  Heme transport and erythropoiesis.

Authors:  Xiaojing Yuan; Mark D Fleming; Iqbal Hamza
Journal:  Curr Opin Chem Biol       Date:  2013-02-14       Impact factor: 8.822

7.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

8.  The Lombardy Rare Donor Programme.

Authors:  Nicoletta Revelli; Maria Antonietta Villa; Cinzia Paccapelo; Maria Cristina Manera; Paolo Rebulla; Anna Rita Migliaccio; Maurizio Marconi
Journal:  Blood Transfus       Date:  2013-02-21       Impact factor: 3.443

9.  Overlapping substrate and inhibitor specificity of human and murine ABCG2.

Authors:  Joshua Bakhsheshian; Matthew D Hall; Robert W Robey; Michelle A Herrmann; Jin-Qiu Chen; Susan E Bates; Michael M Gottesman
Journal:  Drug Metab Dispos       Date:  2013-07-18       Impact factor: 3.922

10.  Highlights From the American Association of Pharmaceutical Scientists/ International Transporter Consortium Joint Workshop on Drug Transporters in Absorption, Distribution, Metabolism, and Excretion: From the Bench to the Bedside - Clinical Pharmacology Considerations.

Authors:  P T Ronaldson; B Bauer; A F El-Kattan; H Shen; L Salphati; S W Louie
Journal:  Clin Pharmacol Ther       Date:  2016-09-13       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.